Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Detsky Mir will buy back shares from minority shareholders at ₽71.5 per share

5/30/23 DSKY

Rostelecom to launch in St. Petersburg production of electronics

5/30/23 RTKM

Board of Directors of Human Stem Cells Institute recommended that dividends be paid for 2022

5/29/23 ABIO

Tinkoff launched an advice service for sellers on marketplaces

5/29/23 T

Alrosa will start restoring the Mir mine in 2023

5/29/23 ALRS

Rosseti North-West reported for 3 months of 2023 by IFRS

5/29/23 MRKZ

Vitaly Mashchitsky's share in Kamaz went to Nikolai Timokhin

5/29/23 KMAZ

Abrau-Durso may increase dividends from 25% to 35% of profits

5/29/23 ABRD

Lenenergo reported for 3 months of 2023 by RAS

5/29/23 LSNG

Samolet's board of directors declared a ₽10 billion buyback

5/29/23 SMLT